Study on the relationship between family history of malignant tumor and clinicopathological characteristics of sporadic papillary thyroid carcinoma_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

YU Xizi , CHEN Chuang , SONG Junlong , FENG Hongfang , TU Yi ,  SUN Shengrong

Department of Breast and Thyroid Surgery, Renmin Hospital of Wuhan University, Wuhan 430060, P. R. China;

Corresponding author：

SUN Shengrong, Email: sun137@sina.com

Keywords：

sporadic papillary thyroid carcinoma; family history of malignant tumor; tumor type; kinship category

DOI：

10.7507/1007-9424.202009064

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Objective To investigate the relationship between family history of malignant tumor (FHOMT) and clinicopathological features of patients with sporadic papillary thyroid carcinoma (PTC), and to provide basis for individualized diagnosis and treatment.Methods Patients admitted to the department of breast and thyroid surgery in Renmin Hospital of Wuhan University from January 1, 2017 to September 30, 2019 for thyroid surgery for the first time and pathologically diagnosed as PTC were collected. According to the presence or absence of FHOMT, tumor type and family member type, their clinicopathological features were compared.Results In 2 123 patients, there were 1 932 patients without FHOMT and 191 patients with FHOMT. The most common FHOMT was the family history of lung cancer (1.80%). Compared with PTC patients without FHOMT, PTC patients with FHOMT had a later onset age (P=0.000), a lower proportion of central lymph node metastasis (P=0.004), and a lower ratio of capsule invasion (P=0.021). PTC patients with respiratory-related FHOMT had a later onset age (P=0.000). PTC patients with male first-degree relatives had a later onset age (P=0.000). And PTC patients whose first-degree relatives were female had a lower proportion of central lymph node metastasis (P=0.007).Conclusion There are differences in onset age, central lymph node metastasis and capsule invasion between PTC patients with and without FHOMT.

Citation： YU Xizi, CHEN Chuang, SONG Junlong, FENG Hongfang, TU Yi, SUN Shengrong. Study on the relationship between family history of malignant tumor and clinicopathological characteristics of sporadic papillary thyroid carcinoma. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2021, 28(6): 757-761. doi: 10.7507/1007-9424.202009064 Copy

1.	Morris LG, Sikora AG, Tosteson TD, et al. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid, 2013, 23(7): 885-891.
2.	Nielsen SM, White MG, Hong S, et al. The Breast-thyroid cancer link: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev, 2016, 25(2): 231-238.
3.	Kim HJ, Park HK, Byun DW, et al. Iodine intake as a risk factor for BRAF mutations in papillary thyroid cancer patients from an iodine-replete area. Eur J Nutr, 2018, 57(2): 809-815.
4.	Fighera TM, Perez CL, Faris N, et al. TSH levels are associated with increased risk of thyroid carcinoma in patients with nodular disease. Endokrynol Pol, 2015, 66(6): 480-485.
5.	Kitahara CM, Gamborg M, Berrington de González A, et al. Childhood height and body mass index were associated with risk of adult thyroid cancer in a large cohort study. Cancer Res, 2014, 74(1): 235-242.
6.	Mannathazhathu AS, George PS, Sudhakaran S, et al. Reproductive factors and thyroid cancer risk: meta-analysis. Head Neck, 2019, 41(12): 4199-4208.
7.	陈禹存, 高晓虹, 曹铭谦, 等. 甲状腺癌危险因素病例对照研究. 中国公共卫生, 2014, 30(7): 955-957.
8.	李煊赫, 范东伟, 姚廷敬. 甲状腺髓样癌的研究进展. 安徽医药, 2019, 23(1): 5-9.
9.	Nixon IJ, Suárez C, Simo R, et al. The impact of family history on non-medullary thyroid cancer. Eur J Surg Oncol, 2016, 42(10): 1455-1463.
10.	Mazeh H, Benavidez J, Poehls JL, et al. In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease. Thyroid, 2012, 22(1): 3-8.
11.	Cao J, Chen C, Chen C, et al. Clinicopathological features and prognosis of familial papillary thyroid carcinoma—a large-scale, matched, case-control study. Clin Endocrinol (Oxf), 2016, 84(4): 598-606.
12.	Kust D, Staničić J, Mateša N. Bethesda thyroid categories and family history of thyroid disease. Clin Endocrinol (Oxf), 2018, 88(3): 468-472.
13.	Xu L, Li G, Wei Q, et al. Family history of cancer and risk of sporadic differentiated thyroid carcinoma. Cancer, 2012, 118(5): 1228-1235.
14.	Memon A, Berrington De González A, Luqmani Y, et al. Family history of benign thyroid disease and cancer and risk of thyroid cancer. Eur J Cancer, 2004, 40(5): 754-760.
15.	Chiappa C, Rovera F, Rausei S, et al. Breast cancer and thyroid diseases: analysis of 867 consecutive cases. J Endocrinol Invest, 2017, 40(2): 179-184.
16.	Zane M, Parello C, Pennelli G, et al. Estrogen and thyroid cancer is a stem affair: A preliminary study. Biomed Pharmacother, 2017, 85(1): 399-411.
17.	Wang P, Lv L, Qi F, et al. Inereased risk of papillary thyroid cancer related to hormonal factorsin women. Tumour Biol, 2015, 36(7): 5127-5132.
18.	姚姣, 曹仁贤, 文芳. 雌激素作为甲状腺癌治疗靶点的研究进展. 现代医药卫生, 2014, 30(1): 60-62.
19.	Pal T, Vogl FD, Chappuis PO, et al. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab, 2001, 86(11): 5307-5312.
20.	Bastos AU, Oler G, Nozima BH, et al. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma. Eur J Endocrinol, 2015, 173(4): 525-540.
21.	Rosell R, Karachaliou N. RET inhibitors for patients with RET fusionpositive and RET wild-type non-small-cell lung cancer. Lancet Oncol, 2016, 17(12): 1623-1625.
22.	AL-Salameh A, Baudy C, Cohen R. Update on multiple endocrine neoplasia type 1and 2. Presse Med, 2018, 47(9): 722-731.
23.	Handkiewicz-Junak D, Czarniecka A, Jarzab B. Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Mol Cell Endocrinol, 2010, 322(1-2): 8-28.
24.	Kowalik A, Kowalska A, Walczyk A, et al. Evaluation of molecular diagnostic approaches for the detection of BRAF p.V600E mutations in papillary thyroid cancer: Clinical implications. PLoS One, 2017, 12(6): e0179691.
25.	Lee J, Lee CR, Ku CR, et al. Association between obesity and BRAFV600E mutation status in patients with papillary thyroid cancer. Ann Surg Oncol, 2015, 22(Suppl 3): 683-690.
26.	Zimmermann MB, Galetti V. Iodine intake as a risk factor for thyroid cancer: a comprehensive review of animal and human studies. Thyroid Res, 2015, 8: 8.
27.	Baltaci AK, Dundar TK, Aksoy F, et al. Changes in the serum levels of trace elements before and after the operation in thyroid cancer patients. Biol Trace Elem Res, 2017, 175(1): 57-64.

1. Morris LG, Sikora AG, Tosteson TD, et al. The increasing incidence of thyroid cancer: the influence of access to care. Thyroid, 2013, 23(7): 885-891.
2. Nielsen SM, White MG, Hong S, et al. The Breast-thyroid cancer link: a systematic review and meta-analysis. Cancer Epidemiol Biomarkers Prev, 2016, 25(2): 231-238.
3. Kim HJ, Park HK, Byun DW, et al. Iodine intake as a risk factor for BRAF mutations in papillary thyroid cancer patients from an iodine-replete area. Eur J Nutr, 2018, 57(2): 809-815.
4. Fighera TM, Perez CL, Faris N, et al. TSH levels are associated with increased risk of thyroid carcinoma in patients with nodular disease. Endokrynol Pol, 2015, 66(6): 480-485.
5. Kitahara CM, Gamborg M, Berrington de González A, et al. Childhood height and body mass index were associated with risk of adult thyroid cancer in a large cohort study. Cancer Res, 2014, 74(1): 235-242.
6. Mannathazhathu AS, George PS, Sudhakaran S, et al. Reproductive factors and thyroid cancer risk: meta-analysis. Head Neck, 2019, 41(12): 4199-4208.
7. 陈禹存, 高晓虹, 曹铭谦, 等. 甲状腺癌危险因素病例对照研究. 中国公共卫生, 2014, 30(7): 955-957.
8. 李煊赫, 范东伟, 姚廷敬. 甲状腺髓样癌的研究进展. 安徽医药, 2019, 23(1): 5-9.
9. Nixon IJ, Suárez C, Simo R, et al. The impact of family history on non-medullary thyroid cancer. Eur J Surg Oncol, 2016, 42(10): 1455-1463.
10. Mazeh H, Benavidez J, Poehls JL, et al. In patients with thyroid cancer of follicular cell origin, a family history of nonmedullary thyroid cancer in one first-degree relative is associated with more aggressive disease. Thyroid, 2012, 22(1): 3-8.
11. Cao J, Chen C, Chen C, et al. Clinicopathological features and prognosis of familial papillary thyroid carcinoma—a large-scale, matched, case-control study. Clin Endocrinol (Oxf), 2016, 84(4): 598-606.
12. Kust D, Staničić J, Mateša N. Bethesda thyroid categories and family history of thyroid disease. Clin Endocrinol (Oxf), 2018, 88(3): 468-472.
13. Xu L, Li G, Wei Q, et al. Family history of cancer and risk of sporadic differentiated thyroid carcinoma. Cancer, 2012, 118(5): 1228-1235.
14. Memon A, Berrington De González A, Luqmani Y, et al. Family history of benign thyroid disease and cancer and risk of thyroid cancer. Eur J Cancer, 2004, 40(5): 754-760.
15. Chiappa C, Rovera F, Rausei S, et al. Breast cancer and thyroid diseases: analysis of 867 consecutive cases. J Endocrinol Invest, 2017, 40(2): 179-184.
16. Zane M, Parello C, Pennelli G, et al. Estrogen and thyroid cancer is a stem affair: A preliminary study. Biomed Pharmacother, 2017, 85(1): 399-411.
17. Wang P, Lv L, Qi F, et al. Inereased risk of papillary thyroid cancer related to hormonal factorsin women. Tumour Biol, 2015, 36(7): 5127-5132.
18. 姚姣, 曹仁贤, 文芳. 雌激素作为甲状腺癌治疗靶点的研究进展. 现代医药卫生, 2014, 30(1): 60-62.
19. Pal T, Vogl FD, Chappuis PO, et al. Increased risk for nonmedullary thyroid cancer in the first degree relatives of prevalent cases of nonmedullary thyroid cancer: a hospital-based study. J Clin Endocrinol Metab, 2001, 86(11): 5307-5312.
20. Bastos AU, Oler G, Nozima BH, et al. BRAF V600E and decreased NIS and TPO expression are associated with aggressiveness of a subgroup of papillary thyroid microcarcinoma. Eur J Endocrinol, 2015, 173(4): 525-540.
21. Rosell R, Karachaliou N. RET inhibitors for patients with RET fusionpositive and RET wild-type non-small-cell lung cancer. Lancet Oncol, 2016, 17(12): 1623-1625.
22. AL-Salameh A, Baudy C, Cohen R. Update on multiple endocrine neoplasia type 1and 2. Presse Med, 2018, 47(9): 722-731.
23. Handkiewicz-Junak D, Czarniecka A, Jarzab B. Molecular prognostic markers in papillary and follicular thyroid cancer: Current status and future directions. Mol Cell Endocrinol, 2010, 322(1-2): 8-28.
24. Kowalik A, Kowalska A, Walczyk A, et al. Evaluation of molecular diagnostic approaches for the detection of BRAF p.V600E mutations in papillary thyroid cancer: Clinical implications. PLoS One, 2017, 12(6): e0179691.
25. Lee J, Lee CR, Ku CR, et al. Association between obesity and BRAFV600E mutation status in patients with papillary thyroid cancer. Ann Surg Oncol, 2015, 22(Suppl 3): 683-690.
26. Zimmermann MB, Galetti V. Iodine intake as a risk factor for thyroid cancer: a comprehensive review of animal and human studies. Thyroid Res, 2015, 8: 8.
27. Baltaci AK, Dundar TK, Aksoy F, et al. Changes in the serum levels of trace elements before and after the operation in thyroid cancer patients. Biol Trace Elem Res, 2017, 175(1): 57-64.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Study on the relationship between family history of malignant tumor and clinicopathological characteristics of sporadic papillary thyroid carcinoma

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content